Search Results for: Alize Pharma II Acquired by
Articles
SPECIAL FEATURE - Injectable Drug Delivery: New Technologies Deliver Biologics & Differentiate Brands September 12, 2017
Contributor Cindy H. Dubin reports on a segment of the drug delivery industry that will see its market revenue double in just 5 years in response to a growing need to deliver highly viscous, high-volume drugs.
SPECIAL FEATURE - Formulation Development & Manufacturing - CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs April 4, 2017
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.
Checkpoint Therapeutics Announces Issuance of US Composition of Matter Patent for Lung Cancer Compound March 6, 2017
Checkpoint Therapeutics, Inc. recently announced that the US Patent and Trademark Office has issued a composition of matter patent for...Dermira Acquires Option to License Exclusive Rights for up to Three Early Stage Programs from Takeda September 18, 2016
Dermira, Inc. recently announced it has entered into an exclusive option and license agreement with Takeda Pharmaceutical Company Limited. Pursuant...COMPUTATIONAL METHODS - Formulation Development: An Innovative, Simulation-Based Approach August 30, 2016
Tom Reynolds, PhD, Matt Wessel, PhD, Sanjay Konagurthu, PhD, and Marshall Crew, PhD, report that computational methods, such as QM and MD simulations, are playing an ever-expanding role in drug discovery and development, and transforming advances in drug development at all stages.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Using a Single Provider Reduces Costs & Risk March 30, 2016
Contributor Cindy H. Dubin highlights several CDMOs that are evolving their models to become their clients’ single provider and to accommodate their more potent, challenging products.
SPECIAL FEATURE - Advancements in Drug Delivery Technologies Tackle Solubility & Bioavailability Challenges February 29, 2016
Contributor Cindy H. Dubin speaks with several innovator companies to learn more about the latest advances in drug delivery to address the challenging issues of solubility and bioavailability today
ADVANCED DELIVERY DEVICES - Implantable Drug-Eluting Devices: A Novel Approach to Patient Care October 6, 2015
Samuel D. Trohman, MBA, Joey L. Glassco, Elena Draganoiu, PhD, and Carey Boyum present developmental and commercial examples of non-biodegradable drug-eluting devices, along with the versatile properties of thermoplastic polyurethanes for the development of effective drug delivery systems.
DNA VACCINE TECHNOLOGY - A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs August 31, 2015
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
Celgene to Acquire Receptos, Advances Leadership in Immune-Inflammatory Diseases July 16, 2015
Celgene Corporation and Receptos, Inc. recently announced the signing of a definitive agreement in which Celgene has agreed to acquire...The CDMO Market: Implications of Patheon's IPO June 10, 2015
By: Patricia Van Arnum, DCAT Editorial Director, posted Tue, Jun 09, 2015 04:42 AM Patheon's announcement this week that it plans to...CAPSULE TECHNOLOGY - Enteric Capsule Drug Delivery Technology - Achieving Protection Without Coating June 2, 2015
Hassan Benameur, PhD, says ECDDT represents a new, faster, and easier means for oral delivery of labile entities, such as peptides, nucleotides, live biopharmaceutical products, and vaccines.
SPECIAL FEATURE - Outsourcing Formulation & Manufacturing Development: Using Data & Unique Approaches to Solve Solubility Issues, Target Profiles & Customize Products March 31, 2015
Contributor Cindy H. Dubin finds that CMOs are embracing development projects in an effort to establish longer-lasting partnerships with their pharma and biotech clients. These contract developers are deploying innovative techniques aimed at improving solubility and fast-tracking products to market.
Capsugel Acquires Ionic Liquids Technology January 12, 2015
Morristown, N.J., and Melbourne, Australia – Capsugel and Monash University recently announced that Capsugel has acquired the intellectual property pertaining...THE SECOND QUADRANT - Outsourcing Solubilization: Making Bioavailability More Broadly Available January 7, 2015
Marshall Crew, PhD, explores how the contract services and manufacturing market has responded to the opportunity presented by the rising numbers of BCS Type II/IV clinical compounds and solubilized commercial products.
Changes & Trends in Solubilization Outsourcing October 9, 2014
By: Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc. Approved drugs over the last thirty-five years are...CLINICAL TRIALS - Recruitment Challenges for Proof-of-Concept Viral Challenge Trials September 3, 2014
Robert Lins, MD, says contrary to most perceptions, patient recruitment is a difficult process, and finding adequate numbers of suitable subjects is frequently the biggest barrier to trial success, and the most common reason why most clinical trials face delays.
SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing - Product Differentiation Is Critical May 8, 2014
Contributor Cindy H. Dubin speaks with several of these suppliers and manufacturers about the importance of customization and differentiation as the key to pharma companies staying competitive in the prefilled syringe space.
Capsugel Enters Agreement With Chiasma May 7, 2014
Capsugel recently announced an agreement with Chiasma, Inc., wherein Capsugel’s Dosage Form Solutions (DFS) business unit is scaling up manufacturing...SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Early-Stage Partnerships Are On The Rise April 2, 2014
Contributor Cindy H. Dubin asked leading CMOs and CDMOs to describe the value-added services they offer with respect to formulation and manufacturing. Solving challenges of insufficient solubility, poor stability, identifying excipient candidates, and particle design topped their list of offerings.
